FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1827364076> ?p ?o ?g. }

• W1827364076 abstract "Introduction: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase, which has been proposed to play a direct role in the pathogenesis of cardiovascular disease. There are two enzymatic pathways for degradation of ADMA: hydrolysis to citrulline by dimethylarginine dimethylaminohydrolase (DDAH) and transamination by alanine-glyoxylate aminotransferase 2 (AGXT2) with formation of asymmetric dimethylguanidino valeric acid (ADGV). The first pathway is well characterized, whereas the physiological role of AGXT2 is still poorly understood. The goal of our study was to test the hypothesis that transgenic overexpression of AGXT2 would lead to lowering of systemic levels of ADMA and improved vasomotor function. Methods and results: We generated transgenic mice (TG) with ubiquitous overexpression of AGXT2 under control of the chicken beta actin (CAG) promoter. Ubiquitous overexpression of the transgene was confirmed by qPCR and Western Blot. TG animals had normal weight and no observed developmental abnormalities. Biochemical data were generated using HPLC-MS/MS. ADMA plasma levels in AGXT2 TG animals were decreased by 15% (p<0.05), whereas ADGV levels were 6 times higher in TG animals in comparison with wild-types (p<0.001). Lung and heart of TG animals exhibited 2 times lower tissue ADMA content in comparison with controls (p<0.05). Isolated aortic rings were used to estimate endothelium-dependent and -independent relaxation in response to acetylcholine (Ach) and sodium nitroprusside (SNP), respectively. Aortas from AGXT2 TG mice demonstrated an increase in maximal response to ACh (p<0.05). There was a similar relaxation in response to SNP in both groups. Conclusions: Our findings show that upregulation of AGXT2 results in lower ADMA levels and improved endothelial-dependent relaxation in vivo. AGXT2 thereby may be a therapeutic target for long-term reduction of systemic ADMA levels and improvement of vascular function in vivo. This is especially important, because all the efforts to develop ADMA-lowering interventions by means of upregulation of DDAH have not been successful so far. Our data suggest that AGXT2 might be a promising drug target for cardiovascular pathologies associated with elevated ADMA levels." @default.
• W1827364076 created "2016-06-24" @default.
• W1827364076 creator A5004322058 @default.
• W1827364076 creator A5008290065 @default.
• W1827364076 creator A5011448945 @default.
• W1827364076 creator A5016795540 @default.
• W1827364076 creator A5019250344 @default.
• W1827364076 creator A5028570218 @default.
• W1827364076 creator A5034627046 @default.
• W1827364076 creator A5036984095 @default.
• W1827364076 creator A5040932572 @default.
• W1827364076 creator A5053809003 @default.
• W1827364076 creator A5053956338 @default.
• W1827364076 creator A5061182191 @default.
• W1827364076 creator A5080157679 @default.
• W1827364076 creator A5087167001 @default.
• W1827364076 date "2015-05-01" @default.
• W1827364076 modified "2023-09-27" @default.
• W1827364076 title "Abstract 373: Transgenic Overexpression of Alanine-glyoxylate Aminotransferase 2 Lowers Tissue Levels of Asymmetric Dimethylarginine and Improves Endothelial Function in Mouse Aortas" @default.
• W1827364076 doi "https://doi.org/10.1161/atvb.35.suppl_1.373" @default.
• W1827364076 hasPublicationYear "2015" @default.
• W1827364076 type Work @default.
• W1827364076 sameAs 1827364076 @default.
• W1827364076 citedByCount "0" @default.
• W1827364076 crossrefType "journal-article" @default.
• W1827364076 hasAuthorship W1827364076A5004322058 @default.
• W1827364076 hasAuthorship W1827364076A5008290065 @default.
• W1827364076 hasAuthorship W1827364076A5011448945 @default.
• W1827364076 hasAuthorship W1827364076A5016795540 @default.
• W1827364076 hasAuthorship W1827364076A5019250344 @default.
• W1827364076 hasAuthorship W1827364076A5028570218 @default.
• W1827364076 hasAuthorship W1827364076A5034627046 @default.
• W1827364076 hasAuthorship W1827364076A5036984095 @default.
• W1827364076 hasAuthorship W1827364076A5040932572 @default.
• W1827364076 hasAuthorship W1827364076A5053809003 @default.
• W1827364076 hasAuthorship W1827364076A5053956338 @default.
• W1827364076 hasAuthorship W1827364076A5061182191 @default.
• W1827364076 hasAuthorship W1827364076A5080157679 @default.
• W1827364076 hasAuthorship W1827364076A5087167001 @default.
• W1827364076 hasConcept C102230213 @default.
• W1827364076 hasConcept C104317684 @default.
• W1827364076 hasConcept C126322002 @default.
• W1827364076 hasConcept C134018914 @default.
• W1827364076 hasConcept C141035611 @default.
• W1827364076 hasConcept C181199279 @default.
• W1827364076 hasConcept C185592680 @default.
• W1827364076 hasConcept C2777468819 @default.
• W1827364076 hasConcept C2777622882 @default.
• W1827364076 hasConcept C2779129087 @default.
• W1827364076 hasConcept C2779856020 @default.
• W1827364076 hasConcept C2779877776 @default.
• W1827364076 hasConcept C515207424 @default.
• W1827364076 hasConcept C519581460 @default.
• W1827364076 hasConcept C55493867 @default.
• W1827364076 hasConcept C68793091 @default.
• W1827364076 hasConcept C71924100 @default.
• W1827364076 hasConcept C86803240 @default.
• W1827364076 hasConceptScore W1827364076C102230213 @default.
• W1827364076 hasConceptScore W1827364076C104317684 @default.
• W1827364076 hasConceptScore W1827364076C126322002 @default.
• W1827364076 hasConceptScore W1827364076C134018914 @default.
• W1827364076 hasConceptScore W1827364076C141035611 @default.
• W1827364076 hasConceptScore W1827364076C181199279 @default.
• W1827364076 hasConceptScore W1827364076C185592680 @default.
• W1827364076 hasConceptScore W1827364076C2777468819 @default.
• W1827364076 hasConceptScore W1827364076C2777622882 @default.
• W1827364076 hasConceptScore W1827364076C2779129087 @default.
• W1827364076 hasConceptScore W1827364076C2779856020 @default.
• W1827364076 hasConceptScore W1827364076C2779877776 @default.
• W1827364076 hasConceptScore W1827364076C515207424 @default.
• W1827364076 hasConceptScore W1827364076C519581460 @default.
• W1827364076 hasConceptScore W1827364076C55493867 @default.
• W1827364076 hasConceptScore W1827364076C68793091 @default.
• W1827364076 hasConceptScore W1827364076C71924100 @default.
• W1827364076 hasConceptScore W1827364076C86803240 @default.
• W1827364076 hasLocation W18273640761 @default.
• W1827364076 hasOpenAccess W1827364076 @default.
• W1827364076 hasPrimaryLocation W18273640761 @default.
• W1827364076 hasRelatedWork W19450309 @default.
• W1827364076 hasRelatedWork W1965278435 @default.
• W1827364076 hasRelatedWork W1969006393 @default.
• W1827364076 hasRelatedWork W2029626898 @default.
• W1827364076 hasRelatedWork W2031570458 @default.
• W1827364076 hasRelatedWork W2041223323 @default.
• W1827364076 hasRelatedWork W2050405548 @default.
• W1827364076 hasRelatedWork W2073124845 @default.
• W1827364076 hasRelatedWork W2097359245 @default.
• W1827364076 hasRelatedWork W2109491971 @default.
• W1827364076 hasRelatedWork W2123993612 @default.
• W1827364076 hasRelatedWork W2358191715 @default.
• W1827364076 hasRelatedWork W2388625791 @default.
• W1827364076 hasRelatedWork W2585326542 @default.
• W1827364076 hasRelatedWork W2745940353 @default.
• W1827364076 hasRelatedWork W2886848768 @default.
• W1827364076 hasRelatedWork W2887299351 @default.
• W1827364076 hasRelatedWork W2888482918 @default.
• W1827364076 hasRelatedWork W2915113681 @default.
• W1827364076 hasRelatedWork W3011880010 @default.
• W1827364076 isParatext "false" @default.
• W1827364076 isRetracted "false" @default.

• next